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Abstract
Background: Neuromyelitis optica (NMO), a severe demyelinating disease, represents itself with optic neuritis and
longitudinally extensive transverse myelitis. Serum NMO-IgG autoantibodies (Abs), a specific finding in NMO patients, target
the water channel protein aquaporin-4 (AQP4), which is expressed as a long (M-1) or a short (M-23) isoform.
Methodology/Principal Findings: The aim of this study was to analyze serum samples from patients with NMO and controls
for the presence and epitope specificity of IgG and IgM anti-AQP4 Abs using an immunofluorescence assay with HEK293
cells expressing M-1 or M-23 human AQP4. We included 56 patients with definite NMO (n=30) and high risk NMO (n=26),
101 patients with multiple sclerosis, 27 patients with clinically isolated syndromes (CIS), 30 patients with systemic lupus
erythematosus (SLE) or Sjo ¨gren’s syndrome, 29 patients with other neurological diseases and 47 healthy controls. Serum
anti-AQP4 M-23 IgG Abs were specifically detected in 29 NMO patients, 17 patients with high risk NMO and two patients
with myelitis due to demyelination (CIS) and SLE. In contrast, IgM anti-AQP4 Abs were not only found in some NMO and
high risk patients, but also in controls. The sensitivity of the M-23 AQP4 IgG assay was 97% for NMO and 65% for high risk
NMO, with a specificity of 100% compared to the controls. Sensitivity with M-1 AQP4 transfected cells was lower for NMO
(70%) and high risk NMO (39%). The conformational epitopes of M-23 AQP4 are the primary targets of NMO-IgG Abs,
whereas M-1 AQP4 Abs are developed with increasing disease duration and number of relapses.
Conclusions: Our results confirm M-23 AQP4-IgG Abs as reliable biomarkers in patients with NMO and high risk syndromes.
M-1 and M-23 AQP4-IgG Abs are significantly associated with a higher number of relapses and longer disease duration.
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Introduction
Neuromyelitis optica (NMO) is a demyelinating neurological
disease defined by optic neuritis (ON) and longitudinally extensive
transverse myelitis (LETM) [1,2]. NMO often leads to severe
disability and even death within several years of disease onset
[1,3]. Since the discovery and validation of NMO-IgG serum
antibodies (Abs) in NMO patients [4,5], NMO is considered to be
a separate disease entity to multiple sclerosis (MS) [6,7,8,9].
Compared to MS, NMO patients have a worse prognosis and
require different treatment strategies according to the dominant
humoral immunopathogenesis in NMO. Thus, early discrimina-
tion from MS enables specific attention for and treatment of NMO
patients [10,11,12,13]. The specificity of NMO-IgG Abs for the
disease led to addition of NMO-IgG Abs to the diagnostic criteria
of NMO [14]. NMO-IgG are especially useful in the early phase of
disease after a first episode of LETM or recurrent ON. More than
half of NMO-IgG seropositive patients with first LETM relapse
within half a year [15]. NMO-IgG Abs have also been detected in
patients with non organ specific autoimmunity such as in systemic
lupus erythematosus (SLE) or Sjo ¨gren syndrome (SS) patients [16].
NMO-IgG Abs target AQP4 [17], the predominant water-channel
protein within the central nervous system (CNS) [18]. AQP4 exists
as two different heterotetramers [19], M-1 and M-23 AQP4,
which result from usage of different start codons [20,21] and vary
in the 23 amino acids in the N terminus of the protein [19].
Contrary to full length AQP4, M-23 AQP4 forms orthogonally
arranged particles (OAPs) [20], which were shown to be potential
targets for antibody binding [20,22].
Although AQP4 antibodies have now been analyzed in several
cohorts of NMO patients worldwide and the importance of AQP4
OAPs has been demonstrated in all of these studies, it is not clear
whether the specificity and sensitivity of the antibody response to
AQP4 differs between these two isoforms. To the best of our
knowledge no systematic study has so far analyzed the immune
response to both AQP4 M-1 and M-23 isoforms in NMO and high
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serum probes of patients with NMO, MS, clinically isolated
syndromes (CIS), other neurological diseases (OND), SLE and
healthy controls (HC) for M-1 and M-23 AQP4-IgG and- IgM.
We were also interested to compare clinical characteristics of
patients showing the antibody response and, in addition, to assess
the value of anti-AQP4 IgM antibodies in our cohort.
Materials and Methods
Patients and serum samples
Serum samples from 30 patients with NMO and 26 patients
with high risk NMO were recruited prospectively from 2007 to
2009 by the Austrian NMO Study-Group from several Austrian
Neurological Departments, or were sent in for AQP4 antibody
testing by the Department of Neurology, University of Heidelberg,
Germany (n=10). The Austrian NMO Study-Group was
established to obtain clinical, neuroradiological and immunolog-
ical data of Austrian patients with definite and high risk NMO, to
enable an early and appropriate treatment, and to determine the
so far unknown prevalence of NMO in Austria. The present study
was approved by the ethical committee of Innsbruck Medical
University (study no. UN3041 257/4.8) and all Austrian patients
gave written informed consent to the study protocol. All German
samples were tested in an anonymized fashion as requested by the
institutional review board of the University of Heidelberg. All
NMO patients met the revised diagnostic criteria of 1999 [1] and
97% of patients showed longitudinally extensive transverse myelitis
extending over more than three vertebral segments. Ninety-seven
percent of definite NMO cases were females (Table 1). The high
risk group of NMO patients comprised two patients with recurrent
ON (8%) and 24 patients with a single episode or recurrent LETM
(92%), including three neuropsychiatric SLE patients and two
patients with neurosarcoidosis. Additionally, we included 101
patients with MS according to the revised ‘‘McDonald Criteria’’
[23]: 64 patients with relapsing remitting MS (RRMS), 13 patients
with primary progressive MS (PPMS) and 24 patients with
secondary progressive MS (SPMS). Moreover, 27 patients with
CIS, 29 patients with various OND (ischemic infarct, parkinson
disease, epileptic seizure, radiculopathy, insomnia, sleep apnoea
syndrome, CNS lymphoma, traumatic brain injury, myasthenia
gravis, chronic inflammatory demyelinating polyneuropathy,
vestibular neuritis, orthostatic syncope, psychogenic neurological
symptoms, CNS vasculitis, hereditary neuropathy, analgesic-
induced headache, neuroborreliosis, viral encephalitis, chronic
tension-type headache, glioblastoma multiforme), 30 patients with
SLE or SS and 47 HC were screened for AQP4-Ig.
Serial blood samples were available from two patients with
recurrent ON who converted to NMO after 2.6 and 8.7 years.
None of the patients was under high-dose methylprednisolone
treatment (HDMP) at the time of blood sampling.
All samples were stored at 220uC until use.
Expression of AQP4 in HEK-293A cells
Human M-1 and M-23 AQP4 isoforms were amplified from a
human adult spinal cord Quick Clone
Tm cDNA library (Clontech-
Takara Bio Europe, Saint-Germain-en-Laye, France) and cloned
into the mammalian expression vector Vivid Colours
TM
pcDNA
TM 6.2C-EmGFP-GW/TOPO (Invitrogen, Carlsbad,
CA, USA). The correct M-1 and M-23 AQP4 insert sequences
were verified by DNA sequencing (Microsynth, Balgach, Switzer-
land). HEK-293A cells (ATCC, LGC Standards GmbH, Wesel,
Germany) were transiently transfected (Fugene 6 transfection
reagent, Roche Applied Sciences, Mannheim, Germany) achiev-
ing over-expression of AQP4 isoforms fused C-terminally to
emerald green fluorescence protein (EmGFP), respectively. The
empty vector served as control. Furthermore, both AQP4 isoforms
were cloned into the pcDNA3.1 Directional TOPO Expression
vector (Invitrogen, Carlsbad, CA, USA), to express M-1 and M-23
AQP4 without the EmGFP fusion protein.
Efficiency of transfection was determined by flow cytometry
(FACScan and Cell Quest pro software, BD Biosciences, San Jose,
CA, USA). The topology of AQP4 was determined via
intracellular staining using a rabbit anti-AQP4 Ab detecting
amino acids 249–323 (Sigma-Aldrich). Cells were fixed with 4%
paraformaldehyde, blocked with goat IgG (Sigma-Aldrich),
incubated with the antibody, washed with phosphate buffered
saline (PBS)/10% FCS and incubated with Cy
Tm3-conjugated
AffiniPure Goat anti-rabbit IgG (Jackson ImmunoResearch
Laboratory, West Grove, PA).
Table 1. Serum antibody binding AQP4 M-1 and M-23 isoforms in different disease groups.
AQP4 NMO High risk NMO MS CIS SLE/SS OND HC p-value
Number 30 26 101 27 30 29 47
Females 29 (97%) 16 (62%) 65 (64%) 21 (78%) 27 (90%) 20 (69%) 39 (83%) 0.001
2
Age (y)
1 49 (18–80) 49 (26–75) 40 (16–68) 35 (19–63) 41 (22–92) 44 (18–84) 43 (21–68) 0.001
3
M-23 IgG 29 (97%) *# 17 (65%) * 0 (0%) 1 (4%) 1 (3%) 0 (0%) 0 (0%) ,0.001
2
M-23 IgG Titer (1:)
1 2,560 (160–20,480) 1,280 (40–10,240) - 640 320 - -
M-1 IgG 21 (70%) * 10 (39%) * 0 (0%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) ,0.001
2
M-1 IgG Titer (1:)
1 160 (40–5,120) 80 (20–2,560) - 40 - - -
M-23 IgM 8 (27%) * 3 (12%) 4 (4%) 1 (4%) 0 (0%) 1 (4%) 0 (0%) ,0.001
2
M-23 IgM Titer (1:)
1 40 (20–80) 80 (20–80) 50 (20–80) 20 - 20 -
M-1 IgM 3 (10%) 2 (8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.001
2
M-1 IgM Titer (1:)
1 40 (20–40) 30 (20–40) - - - - -
1data are shown as median (range), p-value: groups were compared using
2 Chi-Square test and
3 Kruskal-Wallis test and Dunn’s multiple comparison post-hoc test,
*statistically different from HC group at p,0.01,
# statistically different from high risk NMO group at p,0.01.
Abbreviations: n = number of patients, y = years.
doi:10.1371/journal.pone.0010455.t001
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All serum samples were analyzed for the presence of AQP4-IgG
and- IgM by an extracellular live cell staining IF technique as
previously described [24,25,26].
HEK-293A cells were transfected using the expression plasmids
mentioned above and cultured for 72 h. Then, cells were blocked
with goat IgG (Sigma-Aldrich) in PBS/10%FCS, incubated with
pre-absorbed (rabbit liver powder, Sigma-Aldrich) serum samples
(screening dilution 1:20 and 1:40, positive sera were further diluted
until loss of signal), washed and detected with Cy
Tm3-conjugated
goat anti-human IgG or IgM antibody (Jackson ImmunoResearch
Laboratory, West Grove, PA). Dead cells were visualized with
DAPI staining (Sigma-Aldrich) and live cells were analyzed for
AQP4-Ig binding. All samples were assessed by two independent
investigators blinded for any clinical information. Anti-AQP4
antibodies purified from a NMO patient’s plasma by affinity
chromatography served as positive control [25].
Statistical analysis
Statistical analysis (means, medians, range, standard deviations),
significance of group differences and linear regression were
evaluated using SPSS software (release 16.0, SPSS Inc., USA) or
GraphPad Prism 5 (GraphPad, San Diego, USA). Between-group
comparisons were performed with Kruskal-Wallis test, Dunn’s
multiple comparison post-hoc test, Mann-Whitney U test, Fisher’s
exact test and Chi-square test. Correlation of parameters was
analyzed with Spearman’s non-parametric correlation. Statistical
significance was defined as two-sided p-value ,0.05 and
Bonferroni corrections were applied for multiple comparisons
when appropriate.
Results
M-1 and M-23 AQP4-IgG binding results in different
staining patterns
With the advent of AQP4 Abs as biomarkers in NMO [4,17],
various NMO-IgG antibody assays have been developed so far. In
our study we screened serum samples by a live cell staining IF
assay, based on the publication of Takahashi et al [24].
In a first step we verified the AQP4 topology of transfected cells
with the rabbit anti-water channel AQP4 antibody, followed by
the determination of the transfection efficiency via flow cytometry
staining (EmGFP 6865%; M-23 AQP4 6462%; M-1 AQP4
5865%; statistically non-significant). We then analyzed the
presence of anti-AQP4 Abs in patients’ sera by our immunoflu-
orescence assay. As shown in Figure 1 we found co-localization of
NMO Abs (red) with the AQP4 protein (green), whereas NMO
Abs did not bind to EmGFP transfected cells. All serum samples
were screened for the presence of AQP4 M-23 (Figure 1A) and M-
1 IgG (Figure 1B), which resulted in different staining patterns.
Antibody binding to M-23 AQP4 showed a laminar staining
pattern, which could resemble the formation of OAPs. In contrast,
M-1 AQP4 did not form visible OAPs and therefore had a more
point shaped staining pattern (Figure 1).
In order to exclude that EmGFP might influence the formation
of large arrays compared to the non-fused AQP4 proteins we have
also over-expressed M-1 and M-23 proteins without EmGFP. We
observed the same NMO-IgG binding patterns using M-1 and M-
23 AQP4 transfected cells without the EmGFP fusion protein, as
illustrated in Figure 2. Consequently we can exclude that EmGFP
has an influence on the formation of OAPs. Furthermore, EmGFP
fused versus unfused AQP4 M-1 and M-23 transfected cells gave
identical results in a subset of 15 M-1 and M-23 seropositive and
15 M-1 and M-23 seronegative patients.
NMO-IgG mainly targets M-23 AQP4
Anti-AQP4 M-23 specific IgG was detected in 29 of 30 definite
NMO patients and in 17 of 26 patients with high risk NMO
(Table 1). Thus the sensitivity of our assay using M-23 AQP4
transfected cells was 97% for NMO patients and 65% for patients
with suspected NMO. In the high risk NMO group, three patients
with SLE associated LETM and one patient with recurrent ON
were seropositive for anti-AQP4 M-23 IgG. Additionally, M-23
AQP4-IgG was detected in two patients with myelitis due to
demyelination (CIS) and SLE, respectively. Furthermore, all HCs,
patients with MS, OND and non-neuropsychiatric SLE patients
were seronegative for anti-AQP4 M-1 and M-23 IgG. In contrast,
sensitivity with M-1 AQP4 transfected cells was remarkably lower
for clinically definite NMO (70%) and high risk NMO (39%).
Additionally, serum Abs to full length AQP4 were also detected in
the patient with isolated myelitis, but not in the patient with SLE-
myelitis, who were both positive for M-23 AQP4-IgG.
To summarize, weaker binding was observed to full length
AQP4, which is also evident from the lower titer values of M-1
AQP4-IgG (Table 1).
NMO and high risk patients can be classified into three
groups
According to their NMO-IgG serostatus, we classified definite
and high risk NMO patients into three different groups (Table 2):
1) seronegative patients (n=10); 2) patients with Abs against M-23
AQP4 but not against full length AQP4 (n=15); and 3) patients
with Abs against both AQP4 isoforms (n=31). As described
before, AQP4-IgG were predominantly detected in the sera of
female patients: 93% of patients with M-23 AQP4-IgG, 94% of
cases with M-1 and M-23 AQP4-IgG, but only 20% of
seronegative patients.
Whereas only one NMO patient was seronegative for AQP4-
IgG, the majority of patients with Abs against both AQP4 isoforms
(68%) and with Abs against M-23 AQP4 (53%) were diagnosed as
NMO. We found no significant differences in the percentage of
patients with myelits, LETM, ON, cerebral MRI lesions and
oligoclonal bands in the three groups.
M-1 AQP4-IgG seropositivity is significantly associated with a
longer median disease duration (70 months), compared to patients
who were only positive for M-23 AQP4-IgG (45 months) and the
subjects without AQP4 Abs (8 months). Additionally, the median
number of relapses was higher in the M-1 and M-23 AQP4-IgG
double positive group (6) and in the M-1 negative but M-23
AQP4-IgG positive group (4) than in the seronegative patients (1).
Furthermore, median antibody titers to M-23 AQP4 were
significantly higher in the M-1+M-23 AQP4-IgG double positive
group (1:2,560) than those cases only positive for M-23 AQP4-IgG
(1:640).
Additionally, our results show an increase of NMO-IgG titers in
the serum of two patients with recurrent ON after converting into
definite NMO (Figure 3). With increasing M-23 AQP4-IgG titers,
the patient with the longer disease duration developed Abs against
full length AQP4, whereas the second patient remained M-1
AQP4-IgG negative.
NMO-IgM is elevated in definite and high risk NMO
patients
A higher percentage of M-23 IgM Abs was detected in NMO
patients (n=8; 27%) and in the high risk group (n=3; 12%)
compared to the other groups (Table 1). M-23 IgM Abs were also
present in the NMO-IgG seropositive patient with isolated
Antibodies to AQP4 Isoforms
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(4%).
Furthermore, anti-AQP4-IgM Abs to M-1 AQP4 were only
detectable in a small subgroup of patients with definite NMO
(n=3) and high risk NMO (n=2). In contrast to NMO-IgG,
AQP4-IgM positive samples yield much lower titer values
(Table 1).
Discussion
Our assay with living AQP4 M-23 transfected cells is highly
sensitive for detecting anti-AQP4-IgG Abs in definite (97%) and
high risk (65%) NMO patients. Furthermore, we detected M-23
AQP4-IgG in two patients with myelitis (CIS and SLE), who
harbour the risk of later developing NMO and could benefit from
an appropriate early treatment. In contrast, AQP4-IgG Abs were
not present in patients with MS, OND, and non-neuropsychiatric
SLE and in HC, which supports their high relevance as biological
markers. Our results are in concordance with studies showing
highest sensitivity for NMO-IgG detection in cell based assays
[27].
Recent papers suggest stronger NMO-IgG Ab binding directed
to the shorter M-23 AQP4 isoform [22], which in contrast to M-1
AQP4 can form orthogonal arrays (OAPs) [20,28]. Our study
confirms weaker binding of NMO-IgG to full length AQP4,
resulting in a lower sensitivity for clinically definite NMO (70%)
and high risk NMO (39%) patients, besides also the M-23 IgG
seropositive patient with SLE associated myelitis was negative for
full length AQP4-IgG. Consequently the assay with M-23 AQP4
transfected cells is much more reliable for an early identification of
NMO-IgG Abs in serum samples, whereas numerous patients
turned out to be ‘‘false negative’’ when performing the assay with
M-1 AQP4 transfected cells.
NMO-Ig Abs resulted in different staining patterns when
binding to full length AQP4 in contrast to the M-23 AQP4
isoform. We speculate that the laminar staining pattern of M-23
AQP4-IgG is due to the capability of M-23 AQP4 to form OAPs,
which are suggested to be potential targets for Ab binding. On the
contrary, IgG binding to full length AQP4, resulted in a more
point shaped staining pattern. In order to exclude the possibility
that EmGFP has an influence on the formation of OAPs, we
performed the immunofluorescence assay with both AQP4
Figure 1. Different staining patterns of NMO-IgG in M-1 and M-23 AQP4 transfected cells. Anti-AQP4 IgG (red) in NMO patient’s serum
targets AQP4 (green), which is expressed by transiently transfected HEK cells. Performing the assay for M-23 AQP4 (A, green) versus M-1 AQP4 (B,
green), results in different staining patterns of NMO-IgG (red). Weaker binding was observed to M-1 AQP4, which contrary to M-23 AQP4 forms only
few orthogonal arrays of particles.
doi:10.1371/journal.pone.0010455.g001
Antibodies to AQP4 Isoforms
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staining patterns and identical results for serum M-1 and M-23
AQP4-IgG and- IgM seropositive and seronegative samples.
As recent studies suggest a strong correlation of NMO-IgG titres
with the clinical status of disease [24,29] we performed serial
dilutions of NMO Ig positive samples, resulting in higher titer
levels of M-23 AQP4-IgG. Moreover, none of the patients were
only positive for M-1 AQP4-IgG and negative for M-23 AQP4-
IgG, or had higher titer levels for full length AQP4. Possibly, the
differences in sensitivity and specificity of the various published
NMO-IgG Ab assays could be due to the AQP4 isoform [30], in
particular earlier papers do not differentiate between M-1 versus
M-23 AQP4-IgG. According to their AQP4-IgG serostatus, we
could classify definite and high risk NMO patients into three
different groups: AQP4-IgG seronegative patients, patients with
Abs against M-23 AQP4 but not against full length AQP4 and
patients with Abs against both AQP4 isoforms.
Our results indicate a primary NMO-IgG response directed to
an epitope present in the shorter M-23 AQP4 isoform, which
could be an epitope present in OAPs. It seems, however, that with
increasing disease duration and severity, patients develop higher
titers for M-23 AQP4-IgG and additionally target epitopes present
in full length AQP4, thus also M-1 AQP4-IgG titer values increase
with time. This hypothesis is supported by the significant higher
number of relapses and the longer disease duration in patients with
M-1 and M-23 IgG compared to patients who target only M-23
AQP4. Moreover, AQP4-IgG negative patients (definite and high
risk) had the shortest disease duration and lowest number of
relapses. Alternatively, this finding could also be explained by an
affinity maturation of these antibodies like it has been shown for
other high-affinity IgG autoantibodies that have undergone
somatic hypermutation and class switching thus reflecting a
pathologic process [31].
The difference in titer levels was also seen in two patients who
were initially diagnosed with recurrent ON. The M-23 AQP4-IgG
titer was much higher after they had developed definite NMO,
and the patient with longer disease duration developed Abs against
M-1 AQP4.
In comparison to AQP4-IgG, AQP4-IgM Abs are not a reliable
biomarker, although they were elevated in definite and high risk
NMO patients. However, AQP4-IgM were also detected in a low
percentage of patients with MS and OND.
In this study we confirm that AQP4-IgG are useful biomarkers
for early diagnosis of NMO and high risk patients. Our results
suggest M-23 AQP4 as initial and major target antigen for
Table 2. Different features of NMO and High risk patients according to their AQP4 Ab status.
M1-M23- M1-M23+ M1+M23+ p-value
Number 10 15 31
Females 2 (20%) 14 (93%) * 29 (94%) * ,0.001
2
Age (y)
1 40 (26–65) 54 (18–77) 49 (19–80) 0.095
3
Duration (m)
1 8 (0.8–60) 45 (0.1–114) 70 (0.4–540) *# 0.009
3
NMO 1 (10%) 8 (53%) 21 (68%) * 0.006
2
Myelitis 9 (90%) 15 (100%) 30 (97%) 0.413
2
LETM 9 (90%) 15 (100%) 29 (94%) 0.179
2
ON 2 (20%) 8 (53%) 22 (71%) * 0.026
2








1 1 (0–4) 4 (1–13) * 6 (1–15) * ,0.001
3
M-23 IgG Titer
1 - 640 (40–10,240) 2,560 (160–20,480) # ,0.001
4
M-1 IgG Titer
1 - - 160 (20–5,120)
1data are shown as median (range), p-value: groups were compared using
2 Chi-Square test and
3 Kruskal-Wallis test and Dunn’s multiple comparison post-hoc test,





Abbreviations: n = number of patients, y = years, m = months.
doi:10.1371/journal.pone.0010455.t002
Figure 2. NMO-IgG staining patterns in AQP4-EmGFP versus
AQP4 expressing cells. Fusion of EmGFP to AQP4 molecules has no
effect on the formation of the different staining patterns of NMO-IgG in
M-1 and M-23 AQP4 transfected cells. NMO-IgG has the same laminar
staining pattern when binding M-23 AQP4 with and without EmGFP
fusion (A). In contrast, cells transfected with M-1 AQP4-EmGFP and M-1
AQP4 have a more point shaped staining pattern (B).
doi:10.1371/journal.pone.0010455.g002
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Abs to M-1 AQP4 are predominantly developed with increasing
disease duration and severity. Thus we suggest that only M-23
AQP4 should be used as target antigen for the early detection of
AQP4-IgG. AQP4-IgM was elevated in AQP4-IgG positive
patients, however because of lower sensitivity and specificity its
role as biomarker in NMO remains unclear.
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